Accueil
Détail de l'éditeur
Documents disponibles chez cet éditeur (463)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Rapport
This report presents the overview of the drug phenomenon in France, covering drug supply, use and public health problems, as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided t[...]Rapport
In November 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide, commonly known as furanylfentanyl, through a joint assessment. Furanylf[...]Rapport
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017. On the ba[...]Chapitre
The influence of gender not only on patterns and levels of drug consumption in Europe but also on how responses to drug problems are planned and implemented is explored in this Selected issue. Based on a scientific analysis of the available data[...]Rapport
J. HILLEBRAND ; D. OLSZEWSKI ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2008FRANÇAIS : Une inquiétude croissante existe au sein de l'Union européenne quant aux produits chimiques utilisés dans la production de la drogue récréative GHB. Cette déclaration figure dans ce rapport publié dans le cadre de son projet E-POD qu[...]Rapport
OEDT = EMCDDA ; ONUDC / UNODC | New York : UNODC/UNODCCP | Programme mondial d'évaluation de l'abus de drogues / Global Assessment Programme on drug abuse (GAP) | 2007The number of people seeking treatment for drug problems is a leading indicator of drug use patterns and prevalence. Data collected from this group offer a valuable 'window' onto an otherwise hidden population and a means of assessing the perfor[...]Rapport
Prices are an essential element of the illicit drug market, from both a supply and demand perspective. They are an indicator of drug availability and are an important tool for understanding the workings of drug supply mechanisms. They may also b[...]Rapport
G. P. SCALIA TOMBA ; C. ROSSI ; C. TAYLOR ; D. KLEMPOVA ; L. WIESSING | Lisbon : OEDT / EMCDDA | Scientific Reports | 2008Monitoring the incidence of problem drug use - the rate at which people who will become problem users start using or injecting drugs for the first time - plays an important part in tracing new trends in Europe’s drug situation and in helping to [...]Rapport
Infectious diseases are among the most serious health consequences of injecting drug use and can lead to significant healthcare costs. Injecting drug users are vulnerable to a range of infectious and communicable diseases through a variety of ri[...]Rapport
FRANÇAIS : L'EMCDDA cherche à promouvoir des méthodes d'évaluation scientifique dans le champ de la prévention dans le but d'améliorer la qualité des interventions. Les recommandations de ce manuel doivent permettre de comparer les différents [...]Rapport
OEDT = EMCDDA ; C. KROGER ; H. WINTER ; R. SHAW ; L. LEONE | Lisbon : OEDT / EMCDDA | Manuals | 2012The EMCDDA first published the Guidelines for the evaluation of drug prevention in 1998 to respond to a need expressed by professionals and policymakers to have a tool and stimulus to evaluate prevention interventions in Europe. These guidelines[...]Rapport
FRANÇAIS : En octobre 1999 le CHADS (Edimbourg) et l'université d'Amsterdam ont été sollicités dans le cadre de la politique de l'OEDT de mise à disposition d'outils pour les professionnels de la réduction de la demande. Ce projet vise à facil[...]Rapport
ENGLISH : The main objective of the guidelines is to provide a European audience with basic information on the options, elements and procedures of drug-related treatment evaluation. The target readership includes professionals working in treat[...]Rapport
Prevalence of problem drug use (PDU) is one of five key indicators used by the EMCDDA to provide more comparable, scientifically based estimates of the prevalence of more severe patterns of drug use that cannot be reliably measured by surveys. T[...]Rapport
FRANÇAIS : En juin 1997, le Conseil de l'Union Européenne voulant suppléer aux différences de législation sur les nouvelles drogues de synthèse dans les Etats membres de l'Union Européenne, a adopté une action commune permettant l'échange d'in[...]